AlphaRx, Pharmaseed to develop compounds for nervous-system disorders

By Elaine Rigoli

Tampa, Fla., May 11 - AlphaRx, Inc. has entered into a collaboration with PharmaSeed Ltd. under which AlphaRx will be responsible for the synthesis, characterization, formulation, analysis and production of compounds for the potential treatment of central nervous system disorders, such as stroke and multiple sclerosis, which PharmaSeed will evaluate in stroke and multiple-sclerosis models.

The two companies may create a joint venture for the subsequent commercialization of selected molecules arising out of the collaboration, according to a news release.

AlphaRx's lead compounds have shown immune-system modulating properties, low toxicity, rapid onset and potent anti-inflammatory activity in pre-clinical studies conducted by the company, the release said.

Successfully developed, they offer potential for the future of immunomodulation therapy, suitable in the treatment of immune deficiency states that include cancer, AIDS, Alzheimer's disease, multiple sclerosis, stroke, neuro-inflammation and severe acute and chronic inflammatory conditions such as arthritis and colitis.

AlphaRx, based in Markham, Ont., is a biopharmaceutical company addressing various pharmaceutical markets.

PharmaSeed is a biopharmaceutical company specializing in drug-discovery and early development phases located in Nes-Ziona, Israel.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.